The biotech sector is experiencing variable dynamics amidst funding shifts and market uncertainty. Recursion Pharmaceuticals is restructuring with a 20% workforce reduction amid pipeline streamlining and capital market challenges, projecting extended cash runway to 2027. SpliceBio’s successful $135 million Series B round exemplifies continued investor interest in gene therapies. Other funding highlights include a $177 million Series A for Antares Therapeutics and substantial biopharma capital raises in May, totaling $5.55 billion, evidencing resilience despite broader pressures.